Co Diagnostics Stock Valuation

CODX
 Stock
  

USD 3.10  0.04  1.31%   

Do you wonder what the value of Co-Diagnostics is? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Co Diagnostics, is its stock price multiplied by the total number of shares outstanding, calculating Co Diagnostics' enterprise value requires a different approach. It uses Co Diagnostics' balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
Co-Diagnostics owns a latest Real Value of $7.82 per share. The recent price of the firm is $3.1. At this time, the firm appears to be undervalued. Our model approximates the value of Co-Diagnostics from inspecting the firm fundamentals such as Shares Owned by Insiders of 0.87 %, shares outstanding of 30.92 M, and Return On Asset of 0.0467 % as well as reviewing its technical indicators and Probability Of Bankruptcy. In general, we favor acquiring undervalued equities and dropping overvalued equities since, in the future, asset prices and their ongoing real values will grow together.
  
Co Diagnostics Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Co Diagnostics's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
Undervalued
Today 3.10
Please note that Co Diagnostics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Co-Diagnostics is based on 3 months time horizon. Increasing Co Diagnostics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Co-Diagnostics is useful when determining the fair value of the Co Diagnostics stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Co Diagnostics. Since Co Diagnostics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Co Diagnostics Stock. However, Co Diagnostics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
7.81
Real Value
11.11
Upside
Estimating the potential upside or downside of Co-Diagnostics helps investors to forecast how Co Diagnostics stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Co Diagnostics more accurately as focusing exclusively on Co Diagnostics' fundamentals will not take into account other important factors:
Earnings
Estimates (2)
LowProjected EPSHigh
1.111.121.13
Details
Hype
Prediction
LowEstimated ValueHigh
0.163.106.39
Details
3 Analysts
Consensus
LowTarget PriceHigh
15.0022.0029.00
Details

Co Diagnostics Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Co Diagnostics's current stock value. Our valuation model uses many indicators to compare Co Diagnostics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Co Diagnostics competition to find correlations between indicators driving Co Diagnostics's intrinsic value. More Info.
Co-Diagnostics is rated below average in price to book category among related companies. It is rated below average in net asset category among related companies making up about  233,592,588  of Net Asset per Price to Book. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Co Diagnostics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Co Diagnostics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Co Diagnostics' earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Co Diagnostics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Co Diagnostics and how it compares across the competition.

About Co Diagnostics Valuation

The stock valuation mechanism determines the current worth of Co-Diagnostics on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Co-Diagnostics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Co-Diagnostics based exclusively on its fundamental and basic technical indicators. By analyzing Co Diagnostics's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Co Diagnostics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Co Diagnostics. We calculate exposure to Co Diagnostics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Co Diagnostics's related companies.
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection andor analysis of nucleic acid molecules in the United States and internationally. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Co Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 101 people.

Co Diagnostics Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Co Diagnostics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quarterly Earnings Growth Y O Y0.308
Continue to Trending Equities. Note that the Co-Diagnostics information on this page should be used as a complementary analysis to other Co Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Managers module to screen money managers from public funds and ETFs managed around the world.

Complementary Tools for Co Diagnostics Stock analysis

When running Co-Diagnostics price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Co Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Co Diagnostics. If investors know Co Diagnostics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Co Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Co-Diagnostics is measured differently than its book value, which is the value of Co Diagnostics that is recorded on the company's balance sheet. Investors also form their own opinion of Co Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Co Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Co Diagnostics' market value can be influenced by many factors that don't directly affect Co Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Co Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine Co Diagnostics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Co Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.